Found: 7
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2024 · pp. 53–56
Matveeva L.V., Mosina L.M., Kilovataya O.A., Trokhina I.E.
Introduction. An important pathogenetic link in systemic inflammation in ulcerative colitis (UC) is dysregulation of the immune response. The aim of the study: to study pathogenetic changes in the serum level of interleukin (IL)-4 during UC therapy. Methods. 6…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2022 · pp. 39–43
Lapkina E.Z., Esimbekova A.R., Zinchenko I.S., Ruksha T.G.
Introduction. A transition of proliferating cancer cells to a G0 phase of a cell cycle considered to be implicated in cancer cell drug resistance. The aim of the study. A separation of G0-positive melanoma B16 cells fraction that correspond to resting followed…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2020
Musaelyan A.A., Nazarov V.D., Lapin S.V., Chistyakov I.V., Komarov I.V., Tkachenko O.U., Sogoyan M.V., Berdnik E.W., Mazing A.V., Emanuel W.L., Akopov A.L., Orlov S.V., Bagnenko S.F.
Background. Lung cancer is the most frequent cause of cancer mortality. The prevailing type is non-small cell lung cancer (NSCLC), in the treatment of which EGFR tyrosine kinase inhibitors are actively used, as well as a combination of BRAF and MEK inhibitors.…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2017
Mikhailova G.F., Tsepenko V.V., Skoropad V.Yu., Rukhadze G.О., Shkavrova T.G., Golub Е.V.
Introduction. Recent reports have demonstrated patients with malignant neoplasias have different molecular genetic aberrations. But there are few data available concerning patients with multiple primary tumors (MPT). Aim. To study molecular genetic alterations…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2016
Kit O.I., Vodolazhsky D.I., Maksimov A.Yu., Lazutin Yu.N., Pyltsin S.P., Leyman I.A., Makueva A.M.
Introduction. EGFR mutation and EML4-ALK fusion are the most clinically significant genetic alterations in non-small cell lung cancer. Numerous studies have been devoted to EGFR mutations and their association with phenotypic clinical and pathological characte…
Research article2014
Mazurenko N.N., Kushlinskii N.E.
Lung cancer is one of the most common oncologic diseases in the world and the most frequent cause of the death from malignant neoplasms. Last decade’s studies revealed significant number of molecular events leading to the onset and development of non-small cel…
Research article2013
Mazurenko N.N., Tsyganova I.V., Gagarin I.M., Chuev I.V., Mochalnikova V.V., Kolomeytseva A.A., Gorbunova V.A.
Last successful results in target therapy of cancer were achieved with different tyrosine kinases inhibitors (TKI). Target therapy of non-small cell lung cancer (NSCLC) with EGFR inhibitors gefitinib and erlotinib is effective only in patients with somatic mut…